News

News Sep 2, 2016 ESC: IV Stem Cells for Heart Failure: 'A Lot More to Learn' Intravenous infusion of mesenchymal stem cells failed to improve cardiac function in heart failure patients but the treatment did appear to give patients some benefits such as improvement in physical

News Aug 30, 2016 CardioCell reports Phase IIa heart failure data Data presented at the European Society of Cardiology meeting in Rome showed that a single intravenous administration of ischemic-tolerant mesenchymal stem cells (itMSCs) from CardioCell LLC met the primary safety

News Aug 30, 2016 VIDEO - ESC 2016: beneficial effects of allogeneic mesenchymal stem cells in HF patients Javed Butler Describes the main findings from the Phase IIa CardioCell's Heart Failure study on the safety and efficacy of intravenous infusion of ischemia-tolerant allogeneic

News Aug 30, 2016 IV Administration of Stem Cells Viable and More Practical Than Direct Cardiac Implantation MedicalResearch.com Interview with: Javed Butler, M.D., MPH, FACC, FAHA, Chief of the Cardiology Division and Co-Director of the Heart Institute at Stony Brook

News Aug 30, 2016 CardioCell announces positive results from phase IIa study evaluating IV administration of stem cells for chronic HF indications CardioCell LLC, a global biotechnology company that uses allogeneic stem cells for cardiovascular indications, announced data from its

News Aug 29, 2016 CardioCell stem cells ‘improve well-being’ of heart failure patients After Celyad failed to reach its primary endpoints in a stem cell therapy test in heart patients back in June, CardioCell has felt the pressure to deliver--and over the weekend posted broadly

News Aug 29, 2016 CardioCell offers bright spot in stem cell development CardioCell reported positive Phase II data for its intravenous stem cell therapy for the treatment of chronic heart failure at the European Society of Cardiology meeting in Rome on Sunday. The study